Patents by Inventor Paul D. Wightman

Paul D. Wightman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230090437
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a retrovirus vaccine adjuvant.
    Type: Application
    Filed: November 29, 2022
    Publication date: March 23, 2023
    Inventor: Paul D. Wightman
  • Patent number: 11524071
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a coronavirus vaccine adjuvant.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: December 13, 2022
    Assignee: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Publication number: 20210038713
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a coronavirus vaccine adjuvant.
    Type: Application
    Filed: October 15, 2020
    Publication date: February 11, 2021
    Inventor: Paul D. Wightman
  • Patent number: 10821176
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Grant
    Filed: July 8, 2019
    Date of Patent: November 3, 2020
    Assignee: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Patent number: 10723731
    Abstract: Conjugates of an immune response modifier, a linker, and an antigen are disclosed. The linker is represented by formula: wherein A is CH or N, p is in a range from 1 to 50, R? is a bond or -alkylene-O—, R? is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and E is an amine- or thiol-reactive group. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. An antigen modified by the linker is also disclosed.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: July 28, 2020
    Assignee: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Publication number: 20200030441
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Application
    Filed: July 8, 2019
    Publication date: January 30, 2020
    Inventor: Paul D. WIGHTMAN
  • Patent number: 10406142
    Abstract: 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.
    Type: Grant
    Filed: March 6, 2017
    Date of Patent: September 10, 2019
    Assignee: 3M lnnovative Properties Company
    Inventor: Paul D. Wightman
  • Patent number: 10383938
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: August 20, 2019
    Assignee: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Publication number: 20180326051
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Application
    Filed: July 24, 2018
    Publication date: November 15, 2018
    Inventor: Paul D. WIGHTMAN
  • Patent number: 10052380
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: August 21, 2018
    Assignee: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Publication number: 20180200364
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c] quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Application
    Filed: November 27, 2017
    Publication date: July 19, 2018
    Applicant: 3M Innovative Properties Company
    Inventor: Paul D. WIGHTMAN
  • Publication number: 20180186792
    Abstract: Conjugates of an immune response modifier, a linker, and an antigen are disclosed. The linker is represented by formula: wherein A is CH or N, p is in a range from 1 to 50, R? is a bond or -alkylene-O—, R? is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and E is an amine- or thiol-reactive group. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. An antigen modified by the linker is also disclosed.
    Type: Application
    Filed: February 26, 2018
    Publication date: July 5, 2018
    Inventor: Paul D. Wightman
  • Patent number: 9902724
    Abstract: Conjugates of an immune response modifier, a linker, and an antigen are disclosed. The linker is represented by formula: wherein A is CH or N, p is in a range from 1 to 50, R? is a bond or -alkylene-O—, R? is alkylene that is optionally interrupted or terminated with one or more amide or ether groups, and E is an amine- or thiol-reactive group. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed. An antigen modified by the linker is also disclosed.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: February 27, 2018
    Assignee: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Publication number: 20170333553
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Application
    Filed: August 1, 2017
    Publication date: November 23, 2017
    Inventor: Paul D. Wightman
  • Publication number: 20170319712
    Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.
    Type: Application
    Filed: July 27, 2017
    Publication date: November 9, 2017
    Applicant: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: RICHARD L. MILLER, MARK A. TOMAI, ROSS M. KEDL, ISIDRO ANGELO ELEAZAR ZARRAGA, RONNIE ORTIZ, JAMES D. STOESZ, PAUL D. WIGHTMAN
  • Patent number: 9801947
    Abstract: Methods and compositions for enhancing the immune response to an IRM compound by depositing within a localized tissue region an IRM depot preparation that provides an extended residence time of active IRM within the localized tissue region.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: October 31, 2017
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventors: Richard L. Miller, Mark A. Tomai, Ross M. Kedl, Isidro Angelo Eleazar Zarraga, Ronnie Ortiz, James D. Stoesz, Paul D. Wightman
  • Patent number: 9795669
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxyl}butyl)octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: October 24, 2017
    Assignee: 3M INNOVATIVE PROPERTIES COMPANY
    Inventor: Paul D. Wightman
  • Publication number: 20170189521
    Abstract: The compound N-(4-{[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl]oxy}butyl) octadecanamide is a useful drug compound for enhancing immune response and can be used, for example, as a vaccine adjuvant and a cancer treatment.
    Type: Application
    Filed: August 19, 2016
    Publication date: July 6, 2017
    Applicant: 3M Innovative Properties Company
    Inventor: Paul D. Wightman
  • Publication number: 20170173164
    Abstract: 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.
    Type: Application
    Filed: March 6, 2017
    Publication date: June 22, 2017
    Inventor: Paul D. Wightman
  • Patent number: 9642895
    Abstract: Skin penetration enhancers comprising peptides are disclosed. Compositions comprising the skin penetration enhancers are also provided. The compositions further comprise an active agent, such as a pharmaceutically active agent, a vaccine, a cosmetic agent, and a. nutritional supplement. Methods of transdermal ly delivering a pharmaceutically active agent, a vaccine, a cosmetic agent, or a nutritional supplement are also provided.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: May 9, 2017
    Assignee: 3M Innovative Properties Company
    Inventors: Minghua Dai, Dmitri V. Smirnov, Paul D. Wightman